Leading bioelectronics medicine company aims to leverage bioelectronics materials and devices to treat chronic disease.
Aix-en-Provence, FRANCE, and Toronto, CANADA, February 18, 2018. Bioelectronic medicine company Panaxium SAS today announced that it has selected a location for its new permanent R&D Centre in Aix-en-Provence, France. The Centre will be located within the Pôle d’Activités Aix-en-Provence business park.
Bioelectronic medicine is an emerging scientific field that aims to tackle many debilitating and degenerative medical conditions and injuries by leveraging the newest bioelectronics and building imperceptible devices at the microscale dimensions of individual cells. There is significant potential to treat a wide range of diseases such as Traumatic Brain Injuries, Parkinson’s, Alzheimer’s, and even peripheral nerve damage.
“We are excited to be leveraging the resources of the Aix-Marseille area, especially with the growing concentration of specialized talent at the intersection of biomedical and electrical engineering in the region,” says Brad Schmidt, CEO of Panaxium. “Our new dedicated labs and medical-grade facility will enable us to demonstrate the potential of so many recent advancements in our field, and by building these labs we will see this long-held vision of commercializing bioelectronic medicine treatments realized.”
Founded in 2016, Panaxium is a new and rapidly-growing bioelectronic medicine company aiming to fundamentally change the way disease is treated. The company is comprised of a multidisciplinary team of internationally-renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.
For more information, please visit http://www.panaxium.com.